8- The Michigan Daily - SPORTSMonday - Monday, March 21, 1994
Gymnasts close home season in style vs. GW
0
By MELANIE SCHUMAN
DAILY SPORTS WRITER
After Saturday night's decisive
victory over George Washington,
the Michigan women's gymnastics
team finished the regular season with
only one loss and its highest rank-
ing in school history.
An overall record of21-7, and 7-
0 in limited Big Ten competition, is
probably better than Michigan coach
Bev Plocki could have hoped for
when she embarked on her fifth year
guiding the Wolverines.
Before the season, Plocki fo-
cused on the conference meet as the
a would-be climatic finish to an-
other up-and-coming season for the
Wolverines.
A ninth-place finish at the NCAA
Championships last year provided
the motivation for Michigan, which
predicted a 1994 final standing
among the Super Six elite of NCAA
gymnastics.
As of the final week of competi-
tion, Michigan is ranked No. 3, hav-
ing overcome No. 4 and perennial
national-title contender Alabama.
Whether the Wolverines remain
third is not exactly up to them. It
depends on how other teams fared
and whose composite (released
Wednesday) will tally the highest.
"We were pretty pleased," fresh-
man Andrea McDonald said. "We
try not to worry about scores we
can't control. We got caught up in
that for a while."
McDonald placed second in the
all-around against the Colonials with
a 38.725, third on the uneven bars
(9.775) and third on the balance
beam (9.600). After an unsatisfac-
tory week of practice, she was
pleased with her effort.
Michigan, which had hoped to
come out strong on the vault to start
the meet, did just that, as the team
total of 49.125 was its second high-
est for one individual event (floor
score was 49.3).
Junior Beth Wymer carried the
Wolverines with a first-place all-
around finish of 39.250, just shy of
her nation-fbading 39.544 average.
Wymer, who also leads the na-
tion in bars, beam and floor exer-
cise, dominated this weekend's No.
1 slot with high marks, including
another perfect 10 on the floor.
Senior Nicole Bronner, the most
consistent all-arounder for the
Colonials with an average score of
37.408, placed fifth with 37.8750,
her highest mark on the season.
Although finishing behind Wol-
verines, she had three strong indi-
vidual peformances on vault, bars
and floor.
The No. 41 Colonials may leave
Ann Arbor with a loss on their score
card, but they too managed to do
just what they expected.
Even with a few breaks, coach
Margie Cunningham believes her
squad's 188.525 (a season best) is a
solid enough mark to retain its No.
7 regional seed.
The Colonials' "nemesis all
year" has been the uneven bars, and
against Michigan, the event contin-
ued to haunt them.
"We can't let the individual
things affect us as long as long as
we can get the overall we need,"
Cunningham said.
They found that "overall" they
needed and so did Michigan.
"(The season) is not over yet, so
it doesn't even feel like it yet," said
sophomore Wendy Marshall, after
her winning performance on the
beam (9.8). She also nailed a sec-@
ond-place routine on vault (9.9) in
this final regular-season duel.
'Dianna Ranelli placed third this weekend on the floor with a 9.875.
DEADLINE EXTENDED
(there are children who need you)
Teach For America is a national teacher corps which
brings non-education majors into urban and rural public
school classrooms across the country for a two year
commitment. You do not need an education degree.
You do need idealism, a willingness to work with at-risk
children, the dedication to be a great teacher,
and the desire to be part of a corps.
Because the demand for Teach For America teachers
has been so incredible this year, we have extended
our application deadline until
MARCH 25, 1994
However there are a limited number of applications,
so you must act immediately!
Applications may be available at your career service office.
If not, call 1-800/832-1230, ext. 450.
SUGIURA
Continued from page 3
"(Winning the title) never crossed my mind," Webb says. "I was too
preoccupied with being scared."
The distance medley was the second-to-last race of the entire two-day
meet. All Webb could do was wait and brew her cauldron of nervous energy.
But by race time, Webb was ready. Pep talks from teammates and coaches
had prepared her, and now she wanted to do her part.
After the previous night's debacle, McClimon and Babcock were also ready
to race.
"I think Courtney and I both had revenge on our minds from the night
before," McClimon says.
There was no questioning whether Westerby was ready. When your
nickname is "Beast," you don't have a lot of choice but to be fired up.
"I remember Kristin Westerby saying, 'I'm running with the top. Not the
competitors, but the people on my team,"' Webb recalls. "You think about 0
that, and if she feels that way about you, you have to feel that way about
yourself."
All that was left to do was run. After an entire season of pointing at this
race as their shot at a title, after the disappointing 5,000, after the tragedy
in the life of a friend, after the skittishness of a teammate running the
biggest race of her life, all that was left was 4,000 meters of running to be
shared by four women.
They were the fastest entry, but now, they were running in a realm where seed
times and the like hardly mattered. They were running against themselves.
They call these things windows of opportunity. Only for these four athletes,
it wasn't so much a window as it was something closer to the size of a porthole.
But through the sheer force of their collective will, they crashed through
like a battering ram, seizing the glory at the only instant that it was available
to be seized.
The race went off without a hitch. Westerby ran a solid leg and handed off
to Webb, who peeled off a blistering 400. She handed off to McClimon, who
completed her leg in third, giving Babcock a chance to run down the leaders.
Babcock did, and finished in 11:08.60. As it was the event's first running at the
indoor NCAAs, the victory established a collegiate standard.
The emotionally-steely McClimon shed pools of tears. The sizable Michigan
cheering section turned to bedlam. McGuire would find out later that evening, but*
he was on everyone's minds as soon as Babcock finished.
And now, one year or 10 years from now, the result will always be the same.
"The bottom line is that when you look in the NCAA track program every
year, for 1994, you're going to see that Michigan, with those four athletes, won
the national championship in that event," McGuire says. "That's something
that they'll always remember and I'll always remember."
TEACH FOR AMERICA
Applicants who have applied by the January 15, 1994
and March 2, 1994 deadlines are consideredfirst.
Thank you to the thousands who have already applied!
K&cfitron 's{
H
Student Discounts!
320 S. State
ocated in the lower level of
Decker Drugs)
Downstairs
[ours: M, Tu, Th, Fr 9am- 6 pm
wed.& Sat. 9am - 1pm
Attention Graduating Seniors! W
Exciting Sales Opportunities available
with Detroit publishing company
Gale Research, Inc., a major publisher of reference books for libraries and businesses
worldwide, is seeking energetic, highly motivated individuals with a drive to succeed
and the desire to join a dynamic, growth-oriented company.
We offer the right individual the opportunity to:
,Work wMtoa professional d ,ntel
Develop existing accounts and new business
CaNin a defined territory
Sel a broad range of new and estabshed product
Competitive salary plus bonus. Complete benefit package indudes medical, dental
and optical coverage, profit sharing, and retirement plan. Stimulating work environ-
ment in prime downtown location.
Customer or public cpntact experience helpful. Must enjoy working with people and
have a pleasant, professional phone manner. Telemarketing training provided.
To learn more about the aplication process and tell us about yourself, callour 24 hour
line this week: (313)961-7880 CausS asles Recriter
Or send your resume to: ma, h
Equd OpporUy Employer Ip5OtrscO DeMOTM4226
THE MOST INTENSIVE COURSE FOR THE
_
!
.1
.i
D epd- I rov
Contraceptive Injection
(sterile medroxyprogesterone acetate suspension, USP)
WHAT IS DEPO-PROVERA CONTRACEPTIVE INJECTION?
DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intra-
muscular injection (a shot) in the buttock or upper arm once every 3 months. To continue
your contraceptive protection, you must return for your next injection promptly at the end of
3 months. DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to
(but not the same as) the natural hormone progesterone, which is produced by your ovaries
during the second halt of your menstrual cycle. DEPO-PROVERA acts by preventing your
egg cells from ripening. If an egg is not released from the ovaries during your menstrual
cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA also
causes changes in the lining of your uterus that make t less likely for pregnancy to occur.
HOW EFFECTIVE IS DEPO-PROVERA CONTRACEPTIVE INJECTION?
DEPO-PROVERA is over 99% effective, making it one of the most reliable methods of birth
control available. This means that the average annual pregnancy rate is less than one for
every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive
methods depends in part on how reliably each woman uses the method. The effectiveness
of DEPO-PROVERA depends only on the patient retuuming every 3 months for her next
injection. Your health-care provider will help you compare DEPO-PROVERA with other con-
traceptive methods and give you the information you need in order to decide which contra-
ceptive method is the right choice for you.
The following table shows the percent of women who got pregnant while using different
kinds of contraceptive methods. It gives both the lowest expected rate of pregancy (the
rate expected in women who use each method exactly as it should be used) and the typical
rate of pregnancy (which includes women who became pregnant because they forgot to
use their birth control or because they did not follow the directions exactly).
PERCENT OF WOMEN EXPERIENCING AN ACCIDENTAL PREGNANCY
IN THE FIRST YEAR OF CONTINUOUS USE
Method Epected Typical
DEPO-PROVERA 0.3 0.3
Implants (Norplant) 0.3 0.3
Female sterilization 0.2 0.4
Male sterilization 0.1 0.15
Oral contraceptive (pill) - 3
Combined0
Progestogen only 0.5
IUD- 3
Progestasert 2.0-
Copper T 380A 0.8 -
Condom (without spermicide) 2 12
Diaphragm (with spermicide) 6 18
Cervical Cap 6 18
Withdrawal 4 18
Periodic abstinence 1 -9 20
Spermicide alone 3 21
Vaginal Sponge
used before childbirth 6 18
Used after childbirth 9 28
No method 85 85
Souce: Trussellet al; Obstet Gyncoai76:558,1990
WHO SHOULD NOT USE DEPO-PROVERA CONTRACEPTIVE INJECTION?
Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you
think you might be pregnant, have any vaginal bleeding without a known reason, have
had cancer of the breast, have had a stroke, have or have had blood clots (phlebitis) in
your leg, have problems with your liver or liver disease, or are allergic to DEPO-
PROVE (medroxyprogesterone acetate or any of its other ingredients). You will have a
physical examination before your doctor prescribes DEPO-PROVERA. It is important to
tell your doctor if you are taking any prescription or over-the-counter medications or if
you have a family history of breast cancer; an abnormal mammogram (breast x-ray),
fibrocystic breast disease, breast nodules or lumps, or bleeding from your nipples; kidney
disease; irregular or scanty menstrual periods; high blood pressure; migraine headaches;
asthma; epilepsy (convulsions or seizures); diabetes or a family history of diabetes; or a
occur and, therefore, the bleeding that comt..s with your normal menstruation does not take
place. When you stop using DEPO-PROVERA your menstrual period will usually, in time,
return to its normal cycle.
2. Bone Mineral Changes
Use of DEPO-PROVERA may be associated with a decrease in the amount of mineral
stored in your bones. This could increase your risk of developing bane fractures. The rate
of bone mineral loss is greatest in the early years of DEPO-PROVERA use, but after that, it
begins to resemble the normal rate of age-related bone mineral loss.
3. Cancer
Studies of women who have used different forms of contraception found that women who
used DEPO-PROVERA for contraception had no increased overall risk of developing cancer
of the breast, ovary; uterus, cervix, or liver. However, women under 35 years of age whose
first exposure to DEPO-PROVERA was within the previous 4 years may have a slightly
increased risk of developing breast cancer similar to that seen with oral contraceptives.
You should discuss this with your health-care provider.
4. Accidental Pregnancy
Because DEPO-PROVERA is such an effective contraceptive method, the risk of accidental
pregnancy for women who get their shots regularly (every 3 months) is very low. While there
have been reports of an increased risk of low birth weight and neonatal infant death or
other health problems in infants conceived close to the time of injection, such pregnancies
are rare. If you think you may have become pregnant while using DEPO-PROVERA for con-
traception, see your health-care provider as soon as possible.
5. Other Risks
Women who use hormone-based contraceptives may have an increased risk of blood clots
or stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg
will begin to develop outside of the uterus (ectopic pregnancy). While these events are rare,
you should tell your health-care provider if you have any of the problems listed in the next
section.
WHAT SYMPTOMS MAY SIGNAL PROBLEMS WHILE USING DEPO-PROVERA
CONTRACEPTIVE INJECTION?
Call your health-care provider immediately if any of these problems occur following an
injection of DEPO-PROVERA: Sharp chest pain, coughing of blood, or sudden shortness of
breath (indicating a possible clot in the lung); sudden severe headache or vomiting, dizzi-
ness or fainting, problems with your eyesight or speech, weakness, or numbness in an arm
or leg (indicating a possible stroke): severe pain or swelling in the calf (indicating a possible
clot in the leg); unusually heavy vaginal bleeding; severe pain or tenderness in the lower
abdominal area; or persistent pain, pus, or bleeding at the injection site.
WHAT ARE THE POSSIBLE SIDE EFFECTS OF DEPO-PROVERA
CONTRACEPTIVE INJECTION?
1. Weight Gain
You may experience a weight gain while you are using DEPO-PROVERA. About two thirds
of the women who used DEPO-PROVERA in clinical trials reported a weight gain of about 5
pounds during the first year of use. You may continue to gain weight after the first year.
Women in one large study who used DEPO-PROVERA for 2 years gained an average total
of 8.1 pounds over those 2 years, or approximately 4 pounds per year. Women who contin-
ued for 4 years gained an average total of 13.8 pounds over those 4 years, or approximate-
ly 3.5 pounds per year. Women who continued for 6 years gained an average total of 16.5
pounds over those 6 years, or approximately 2.75 pounds per year.
2. Other Side Effects
In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some
women reported the following effects that may or may not have been related to their use of
DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness,
abdominal cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps,
nausea, vaginal discharge or irritation, breast swelling and tendemess, bloating, swelling of
the hands or feet, backache, depression, insomnia, acne, pelvic pain, no hair growth or
excessiveshair loss, rash, and hot flashes. Other problems were reported by very few of the
women in the clinical trials, but some of these could be serious. These include convulsions,
jaundice, urinary tract infections, allergic reactions, fainting, paralysis, osteoporosis, lack of
return to fertility, deep vein thrombosis, pulmonary embolus, breast cancer, or cervical can-
cer. If these or any other problems occur during your use of DEPO-PROVERA, discuss
them with your health-care provider.
SHOULD ANY PRECAUTIONS BE FOLLOWED DURING USE OF DEPO-PROVERA
CONTRACEPTIVE INJECTION?
1. Missed Periods
During the time you are using DEPO-PROVERA for contraception, you may skip a period,
or your periods may stop completely. If you have been receiving your DEPO-PROVERA
injections regularly every 3 months, then you are probably not pregnant. However, if you
think that you may be pregnant, see your health-care provider.
2. Laboratory Test Interactions
If you are scheduled for any laboratory tests, tell your health-care provider that you are
using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones
such as DEPO-PROVERA.
3. Drug Interactions
Cytadren (aminoglutethimide) is an anticancer drug that may significantly decrease the
k
A
T
Cofumfiia fJMCT eview
Sering the U ofMfpre- medicaf community
M.D. 'S TRAINING M.D.'S-OF-THE-FUTURE
A
Intensive MCAT preparation & medical school
application/admissions assistance are all we do!.
> MCAT experts: an independent course taught by
academic M.D.'s, top U ofM M.D. & Ph.D.
candidates, & English Department faculty.
A 13 weeks (150+ hours) of detailed in-class instruction
& real MCAT testing, problem solving, reading &
writing workshops, review groups, med school
application & admissions strategies, & tutoring.
) 2000 pages of original take-home review notes,
reading & writing studyguides, MCAT & admissions
strategy handouts, problem sets, & MCAT-quality
timed practice exams.
> Real MCAT testing for in-class & take-home practice.
> Direct contact with young does & med students!
> Tutoring & med school application help included.
> Lower tuition than other courses.
S
0